Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages

1 Research Service and 3 Department of Medicine, Section of Metabolism, Endocrinology, and Nutrition, Phoenix Veterans Affairs Health Care System, Phoenix, Arizona; and 2 Division of Pediatric Endocrinology and Diabetes, University of Ulm, Ulm, Germany Submitted 19 December 2008 ; accepted in final...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology: endocrinology and metabolism Vol. 296; no. 5; pp. E1076 - E1084
Main Authors Permana, Paska A, Zhang, Weiyang, Wabitsch, Martin, Fischer-Posovszky, Pamela, Duckworth, William C, Reaven, Peter D
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.05.2009
Subjects
Online AccessGet full text
ISSN0193-1849
1522-1555
DOI10.1152/ajpendo.91013.2008

Cover

Loading…
Abstract 1 Research Service and 3 Department of Medicine, Section of Metabolism, Endocrinology, and Nutrition, Phoenix Veterans Affairs Health Care System, Phoenix, Arizona; and 2 Division of Pediatric Endocrinology and Diabetes, University of Ulm, Ulm, Germany Submitted 19 December 2008 ; accepted in final form 19 February 2009 Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized that pioglitazone (Pio) could specifically reduce the inflammatory response of adipocytes to factors released by monocytes/macrophages. We show that macrophage factors (M -factors) greatly increase expression levels of proinflammatory adipokines, chemokines, and adhesion molecules in human subcutaneous and visceral adipose tissue (SAT and VAT) as well as in adipocytes (up to several hundredfold of control). Compared with SAT, VAT showed enhanced basal and M -factor-induced inflammatory responses. M -factors also induced greater lipolysis in adipocytes, as assessed by concentrations of glycerol released from the cells (196 ± 13 vs. 56 ± 7 µM in control, P < 0.05). Pretreatment of adipose tissue or adipocytes with Pio reduced these responses to M -factors (by 13–86%, P < 0.05) and prevented M -factor suppression of adiponectin expression. Furthermore, Pio pretreatment of adipocytes and macrophages tended to further reduce inflammatory responses of adipocytes to M -factors and monocyte adhesion to M -factor-activated adipocytes. In support of these in vitro data, media conditioned by monocytes isolated from impaired glucose-tolerant subjects treated with Pio (compared with placebo) induced release of lower concentrations of proinflammatory adipokines and glycerol (100 ± 7 vs. 150 ± 15 µM, P < 0.05) from adipocytes. In summary, Pio decreases inflammatory responses in adipose tissue/cells induced by monocytes/macrophages by acting on either or both cell types. These beneficial effects of Pio may attenuate proinflammatory responses resulting from monocyte/macrophage infiltration into adipose tissue and suppress tissue inflammation resulting from the interaction between both cell types. subcutaneous; visceral; adipose; cross talk; inflammation Address for reprint requests and other correspondence: P. A. Permana, CS/111E, Phoenix Veterans Affairs Health Care System, 650 E. Indian School Rd., Phoenix, AZ 85012-1892 (e-mail: Paska.Permana{at}va.gov )
AbstractList Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized that pioglitazone (Pio) could specifically reduce the inflammatory response of adipocytes to factors released by monocytes/macrophages. We show that macrophage factors (Mphi-factors) greatly increase expression levels of proinflammatory adipokines, chemokines, and adhesion molecules in human subcutaneous and visceral adipose tissue (SAT and VAT) as well as in adipocytes (up to several hundredfold of control). Compared with SAT, VAT showed enhanced basal and Mphi-factor-induced inflammatory responses. Mphi-factors also induced greater lipolysis in adipocytes, as assessed by concentrations of glycerol released from the cells (196 +/- 13 vs. 56 +/- 7 microM in control, P < 0.05). Pretreatment of adipose tissue or adipocytes with Pio reduced these responses to Mphi-factors (by 13-86%, P < 0.05) and prevented Mphi-factor suppression of adiponectin expression. Furthermore, Pio pretreatment of adipocytes and macrophages tended to further reduce inflammatory responses of adipocytes to Mphi-factors and monocyte adhesion to Mphi-factor-activated adipocytes. In support of these in vitro data, media conditioned by monocytes isolated from impaired glucose-tolerant subjects treated with Pio (compared with placebo) induced release of lower concentrations of proinflammatory adipokines and glycerol (100 +/- 7 vs. 150 +/- 15 microM, P < 0.05) from adipocytes. In summary, Pio decreases inflammatory responses in adipose tissue/cells induced by monocytes/macrophages by acting on either or both cell types. These beneficial effects of Pio may attenuate proinflammatory responses resulting from monocyte/macrophage infiltration into adipose tissue and suppress tissue inflammation resulting from the interaction between both cell types.
1 Research Service and 3 Department of Medicine, Section of Metabolism, Endocrinology, and Nutrition, Phoenix Veterans Affairs Health Care System, Phoenix, Arizona; and 2 Division of Pediatric Endocrinology and Diabetes, University of Ulm, Ulm, Germany Submitted 19 December 2008 ; accepted in final form 19 February 2009 Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized that pioglitazone (Pio) could specifically reduce the inflammatory response of adipocytes to factors released by monocytes/macrophages. We show that macrophage factors (M -factors) greatly increase expression levels of proinflammatory adipokines, chemokines, and adhesion molecules in human subcutaneous and visceral adipose tissue (SAT and VAT) as well as in adipocytes (up to several hundredfold of control). Compared with SAT, VAT showed enhanced basal and M -factor-induced inflammatory responses. M -factors also induced greater lipolysis in adipocytes, as assessed by concentrations of glycerol released from the cells (196 ± 13 vs. 56 ± 7 µM in control, P < 0.05). Pretreatment of adipose tissue or adipocytes with Pio reduced these responses to M -factors (by 13–86%, P < 0.05) and prevented M -factor suppression of adiponectin expression. Furthermore, Pio pretreatment of adipocytes and macrophages tended to further reduce inflammatory responses of adipocytes to M -factors and monocyte adhesion to M -factor-activated adipocytes. In support of these in vitro data, media conditioned by monocytes isolated from impaired glucose-tolerant subjects treated with Pio (compared with placebo) induced release of lower concentrations of proinflammatory adipokines and glycerol (100 ± 7 vs. 150 ± 15 µM, P < 0.05) from adipocytes. In summary, Pio decreases inflammatory responses in adipose tissue/cells induced by monocytes/macrophages by acting on either or both cell types. These beneficial effects of Pio may attenuate proinflammatory responses resulting from monocyte/macrophage infiltration into adipose tissue and suppress tissue inflammation resulting from the interaction between both cell types. subcutaneous; visceral; adipose; cross talk; inflammation Address for reprint requests and other correspondence: P. A. Permana, CS/111E, Phoenix Veterans Affairs Health Care System, 650 E. Indian School Rd., Phoenix, AZ 85012-1892 (e-mail: Paska.Permana{at}va.gov )
Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized that pioglitazone (Pio) could specifically reduce the inflammatory response of adipocytes to factors released by monocytes/macrophages. We show that macrophage factors (Mφ-factors) greatly increase expression levels of proinflammatory adipokines, chemokines, and adhesion molecules in human subcutaneous and visceral adipose tissue (SAT and VAT) as well as in adipocytes (up to several hundredfold of control). Compared with SAT, VAT showed enhanced basal and Mφ-factor-induced inflammatory responses. Mφ-factors also induced greater lipolysis in adipocytes, as assessed by concentrations of glycerol released from the cells (196 ± 13 vs. 56 ± 7 μM in control, P < 0.05). Pretreatment of adipose tissue or adipocytes with Pio reduced these responses to Mφ-factors (by 13–86%, P < 0.05) and prevented Mφ-factor suppression of adiponectin expression. Furthermore, Pio pretreatment of adipocytes and macrophages tended to further reduce inflammatory responses of adipocytes to Mφ-factors and monocyte adhesion to Mφ-factor-activated adipocytes. In support of these in vitro data, media conditioned by monocytes isolated from impaired glucose-tolerant subjects treated with Pio (compared with placebo) induced release of lower concentrations of proinflammatory adipokines and glycerol (100 ± 7 vs. 150 ± 15 μM, P < 0.05) from adipocytes. In summary, Pio decreases inflammatory responses in adipose tissue/cells induced by monocytes/macrophages by acting on either or both cell types. These beneficial effects of Pio may attenuate proinflammatory responses resulting from monocyte/macrophage infiltration into adipose tissue and suppress tissue inflammation resulting from the interaction between both cell types.
Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized that pioglitazone (Pio) could specifically reduce the inflammatory response of adipocytes to factors released by monocytes/ macrophages. We show that macrophage factors (M...-factors) greatly increase expression levels of proinflammatory adipokines, chemokines, and adhesion molecules in human subcutaneous and visceral adipose tissue (SAT and VAT) as well as in adipocytes (up to several hundredfold of control). Compared with SAT, VAT showed enhanced basal and M...-factor-induced inflammatory responses. M...-factors also induced greater lipolysis in adipocytes, as assessed by concentrations of glycerol released from the cells (196 ± 13 vs. 56 ± 7 ...M in control, P < 0.05). Pretreatment of adipose tissue or adipocytes with Pio reduced these responses to M...-factors (by 13 - 86%, P < 0.05) and prevented M...- factor suppression of adiponectin expression. Furthermore, Pio pretreatment of adipocytes and macrophages tended to further reduce inflammatory responses of adipocytes to M...-factors and monocyte adhesion to M -factor-activated adipocytes. In support of these in vitro data, media conditioned by monocytes isolated from impaired glucose-tolerant subjects treated with Pio (compared with placebo) induced release of lower concentrations of proinflammatory adipokines and glycerol (100 ± 7 vs. 150 ± 15 ...M, P < 0.05) from adipocytes. In summary, Pio decreases inflammatory responses in adipose tissue/cells induced by monocytes/macrophages by acting on either or both cell types. These beneficial effects of Pio may attenuate proinflammatory responses resulting from monocyte/macrophage infiltration into adipose tissue and suppress tissue inflammation resulting from the interaction between both cell types. (ProQuest: ... denotes formulae/symbols omitted.)
Author Zhang, Weiyang
Wabitsch, Martin
Fischer-Posovszky, Pamela
Reaven, Peter D
Permana, Paska A
Duckworth, William C
Author_xml – sequence: 1
  fullname: Permana, Paska A
– sequence: 2
  fullname: Zhang, Weiyang
– sequence: 3
  fullname: Wabitsch, Martin
– sequence: 4
  fullname: Fischer-Posovszky, Pamela
– sequence: 5
  fullname: Duckworth, William C
– sequence: 6
  fullname: Reaven, Peter D
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19240250$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAUha2qiE4LL8ACRSzYZeqfcRIvUdUCUiVYwNpynJuJR4kdbEcoffreMtMuumBl6fg7x773XJJzHzwQ8oHRLWOSX5vDDL4LW8UoE1tOaXNGNnjBSyalPCcbypQoWbNTF-QypQOltJY7_pZcMMV3lEu6IeNPF_ajy-YBs4sI3WIhFc73o5kmk0NcUUxz8Anl0BfDMhlfmM7Nwa4ZtRyK3lgEU5HARsjQFe1aTMEfgevJ2BjmwewhvSNvejMmeH86r8jvu9tfN9_K-x9fv998uS_tTohcStU2tsUZuhqjpamhgr6Xkgpam0owYRjO33DBQYFVApQBKnvZ1B1veafEFfl8zJ1j-LNAynpyycI4Gg9hSbqqmcRtUQQ_vQIPYYke_6YxXeAjDUPo4wla2gk6PUc3mbjq5yUi0BwBHDSlCL22uNDsgs_RuFEzqp_60qe-9L--9FNfaOWvrC_p_zNtj6bB7Ye_LoKehzW5MIb9-sJzVWmpbxmtK_EIiGis8Q
CODEN AJPMD9
CitedBy_id crossref_primary_10_1007_s10522_020_09861_3
crossref_primary_10_1016_j_phrs_2016_02_027
crossref_primary_10_1194_jlr_R024505
crossref_primary_10_3945_jn_109_120022
crossref_primary_10_4137_CMED_S5372
crossref_primary_10_1074_jbc_M109_033951
crossref_primary_10_1371_journal_pone_0077306
crossref_primary_10_1152_ajpcell_00340_2009
crossref_primary_10_1186_1758_5996_6_47
crossref_primary_10_1016_j_bbrc_2010_10_104
crossref_primary_10_1016_j_arcmed_2010_02_010
crossref_primary_10_1074_jbc_M110_123174
crossref_primary_10_1016_j_ijcard_2014_11_099
crossref_primary_10_1016_j_jss_2014_03_007
crossref_primary_10_1016_j_diabres_2015_06_005
crossref_primary_10_3390_nu11030512
crossref_primary_10_1007_s00380_018_1143_3
crossref_primary_10_1017_S0029665109990206
Cites_doi 10.1016/j.amjcard.2003.11.017
10.1038/34178
10.1096/fj.00-0020com
10.1152/ajpendo.00002.2004
10.1161/CIRCULATIONAHA.107.724096
10.2337/diabetes.53.4.1060
10.1172/JCI116821
10.1016/S0140-6736(05)67528-9
10.1210/jc.2002-020135
10.1007/s00125-004-1612-3
10.1210/en.2003-1336
10.2337/db08-0872
10.1093/nar/gng154
10.1038/sj.ijo.0801792
10.1001/jama.286.3.327
10.1074/jbc.M011695200
10.1161/ATVBAHA.108.175687
10.1210/jc.2005-0369
10.1172/JCI200319246
10.1161/01.ATV.0000183883.72263.13
10.1016/j.nut.2003.09.020
10.1016/j.bbrc.2006.01.012
10.1016/j.bbrc.2003.10.013
10.1073/pnas.1031789100
10.1161/01.ATV.0000251608.09329.9a
10.2337/diabetes.53.5.1285
10.1161/01.ATV.0000200226.53994.09
10.1006/meth.2001.1262
10.1210/jc.2006-1465
10.1007/s00125-006-0190-y
10.1194/jlr.M600235-JLR200
10.1016/j.bbrc.2004.04.010
10.1038/sj.ijo.0801520
10.1038/83336
10.1016/j.bbrc.2007.04.092
10.2337/diabetes.51.5.1319
10.2337/diabetes.52.11.2784
10.1074/jbc.M504611200
10.1002/jcb.10565
10.1073/pnas.1133870100
10.2174/187152807780832265
10.1055/s-2007-978682
10.2337/diabetes.54.8.2305
10.1038/sj.ijo.0802853
10.1074/jbc.M706762200
10.1042/bst0290072
10.1161/01.CIR.101.13.1519
10.1172/JCI200319451
10.1074/jbc.M601284200
10.1530/eje.0.1480535
10.1016/S0303-7207(01)00394-X
10.1016/j.cmet.2007.06.010
10.2337/db07-0218
10.1152/ajpendo.90323.2008
10.1074/jbc.M710314200
10.1016/S0014-5793(03)01040-8
10.1016/S0006-291X(03)00418-2
10.1016/S0014-2999(00)00461-1
10.1038/sj.ijo.0802176
10.1038/nsmb.1447
10.1038/nature03988
10.1016/S1043-4666(02)00495-7
10.1074/jbc.M206999200
ContentType Journal Article
Copyright Copyright American Physiological Society May 2009
Copyright_xml – notice: Copyright American Physiological Society May 2009
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TS
7U7
C1K
7X8
DOI 10.1152/ajpendo.91013.2008
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Physical Education Index
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Toxicology Abstracts
Calcium & Calcified Tissue Abstracts
Physical Education Index
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

CrossRef
Toxicology Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1522-1555
EndPage E1084
ExternalDocumentID 1688505461
19240250
10_1152_ajpendo_91013_2008
ajpendo_296_5_E1076
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Feature
GroupedDBID -
23M
2WC
39C
4.4
53G
5GY
5VS
8M5
ABPTK
ACPRK
ADACO
ADBBV
AENEX
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKOMP
C1A
DIK
DL
E3Z
EBS
EJD
F5P
GX1
H13
KQ8
O0-
OK1
P2P
PQEST
PQQKQ
RAP
RHF
RHI
RPL
WH7
WOQ
---
6J9
AAYXX
ABJNI
BKKCC
BTFSW
CITATION
EMOBN
ITBOX
P6G
RPRKH
TR2
W8F
XSW
YSK
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TS
7U7
C1K
7X8
ID FETCH-LOGICAL-c433t-59b8cb155d7fac5a7e6eff550307a6313a11158232e9ec93e9ae05f587d2b2d93
ISSN 0193-1849
IngestDate Thu Jul 10 17:14:08 EDT 2025
Mon Jun 30 10:30:22 EDT 2025
Mon Jul 21 05:58:47 EDT 2025
Tue Jul 01 03:18:12 EDT 2025
Thu Apr 24 23:01:52 EDT 2025
Tue Jan 05 17:54:16 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c433t-59b8cb155d7fac5a7e6eff550307a6313a11158232e9ec93e9ae05f587d2b2d93
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
PMID 19240250
PQID 232315881
PQPubID 48583
ParticipantIDs proquest_miscellaneous_67150080
highwire_physiology_ajpendo_296_5_E1076
proquest_journals_232315881
crossref_citationtrail_10_1152_ajpendo_91013_2008
crossref_primary_10_1152_ajpendo_91013_2008
pubmed_primary_19240250
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20090501
2009-05-00
2009-May
PublicationDateYYYYMMDD 2009-05-01
PublicationDate_xml – month: 05
  year: 2009
  text: 20090501
  day: 01
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bethesda
PublicationTitle American journal of physiology: endocrinology and metabolism
PublicationTitleAlternate Am J Physiol Endocrinol Metab
PublicationYear 2009
Publisher American Physiological Society
Publisher_xml – name: American Physiological Society
References R61
R60
R63
R62
R21
R20
R23
R22
R25
R24
R27
R26
R29
R28
R1
R2
R3
R4
R5
R6
R7
R8
R9
R30
R32
R31
R34
R33
R36
R35
R38
R37
R39
R41
R40
R43
R42
R45
R44
R47
R46
R49
R48
R50
R52
R51
R10
R54
R53
R12
R56
R11
R55
R14
R58
R13
R57
R16
R15
R59
R18
R17
R19
References_xml – ident: R12
  doi: 10.1016/j.amjcard.2003.11.017
– ident: R42
  doi: 10.1038/34178
– ident: R47
  doi: 10.1096/fj.00-0020com
– ident: R2
  doi: 10.1152/ajpendo.00002.2004
– ident: R5
  doi: 10.1161/CIRCULATIONAHA.107.724096
– ident: R25
  doi: 10.2337/diabetes.53.4.1060
– ident: R17
  doi: 10.1172/JCI116821
– ident: R13
  doi: 10.1016/S0140-6736(05)67528-9
– ident: R50
  doi: 10.1210/jc.2002-020135
– ident: R19
  doi: 10.1007/s00125-004-1612-3
– ident: R14
  doi: 10.1210/en.2003-1336
– ident: R36
  doi: 10.2337/db08-0872
– ident: R56
  doi: 10.1093/nar/gng154
– ident: R15
  doi: 10.1038/sj.ijo.0801792
– ident: R41
  doi: 10.1001/jama.286.3.327
– ident: R32
  doi: 10.1074/jbc.M011695200
– ident: R63
  doi: 10.1161/ATVBAHA.108.175687
– ident: R10
  doi: 10.1210/jc.2005-0369
– ident: R57
  doi: 10.1172/JCI200319246
– ident: R51
  doi: 10.1161/01.ATV.0000183883.72263.13
– ident: R27
  doi: 10.1016/j.nut.2003.09.020
– ident: R40
  doi: 10.1016/j.bbrc.2006.01.012
– ident: R30
  doi: 10.1016/j.bbrc.2003.10.013
– ident: R58
  doi: 10.1073/pnas.1031789100
– ident: R52
  doi: 10.1161/01.ATV.0000251608.09329.9a
– ident: R9
  doi: 10.2337/diabetes.53.5.1285
– ident: R62
  doi: 10.1161/01.ATV.0000200226.53994.09
– ident: R34
  doi: 10.1006/meth.2001.1262
– ident: R29
  doi: 10.1210/jc.2006-1465
– ident: R22
  doi: 10.1007/s00125-006-0190-y
– ident: R3
  doi: 10.1194/jlr.M600235-JLR200
– ident: R44
  doi: 10.1016/j.bbrc.2004.04.010
– ident: R55
  doi: 10.1038/sj.ijo.0801520
– ident: R8
  doi: 10.1038/83336
– ident: R31
  doi: 10.1016/j.bbrc.2007.04.092
– ident: R43
  doi: 10.2337/diabetes.51.5.1319
– ident: R28
  doi: 10.2337/diabetes.52.11.2784
– ident: R38
  doi: 10.1074/jbc.M504611200
– ident: R48
  doi: 10.1002/jcb.10565
– ident: R45
  doi: 10.1073/pnas.1133870100
– ident: R59
  doi: 10.2174/187152807780832265
– ident: R6
  doi: 10.1055/s-2007-978682
– ident: R11
  doi: 10.2337/diabetes.54.8.2305
– ident: R21
  doi: 10.1038/sj.ijo.0802853
– ident: R37
  doi: 10.1074/jbc.M706762200
– ident: R1
  doi: 10.1042/bst0290072
– ident: R46
  doi: 10.1161/01.CIR.101.13.1519
– ident: R60
  doi: 10.1172/JCI200319451
– ident: R24
  doi: 10.1074/jbc.M601284200
– ident: R7
  doi: 10.1530/eje.0.1480535
– ident: R18
  doi: 10.1016/S0303-7207(01)00394-X
– ident: R4
  doi: 10.1016/j.cmet.2007.06.010
– ident: R20
  doi: 10.2337/db07-0218
– ident: R35
  doi: 10.1152/ajpendo.90323.2008
– ident: R49
  doi: 10.1074/jbc.M710314200
– ident: R54
  doi: 10.1016/S0014-5793(03)01040-8
– ident: R23
  doi: 10.1016/S0006-291X(03)00418-2
– ident: R26
  doi: 10.1016/S0014-2999(00)00461-1
– ident: R61
  doi: 10.1038/sj.ijo.0802176
– ident: R33
  doi: 10.1038/nsmb.1447
– ident: R39
  doi: 10.1038/nature03988
– ident: R16
  doi: 10.1016/S1043-4666(02)00495-7
– ident: R53
  doi: 10.1074/jbc.M206999200
SSID ssj0007542
Score 2.0403225
Snippet 1 Research Service and 3 Department of Medicine, Section of Metabolism, Endocrinology, and Nutrition, Phoenix Veterans Affairs Health Care System, Phoenix,...
Infiltration of monocyte-derived macrophages into adipose tissue may contribute to tissue and systemic inflammation and insulin resistance. We hypothesized...
SourceID proquest
pubmed
crossref
highwire
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage E1076
SubjectTerms Adhesion
Adipocytes - drug effects
Adipocytes - immunology
Adipokines - biosynthesis
Adipokines - genetics
Adipose tissue
Cell adhesion & migration
Cells
Chemokine CCL2 - biosynthesis
Chemokine CCL2 - genetics
Enzyme-Linked Immunosorbent Assay
Gene expression
Humans
Hypoglycemic Agents - pharmacology
Infiltration
Inflammation Mediators - immunology
Inflammation Mediators - metabolism
Interleukin-6 - biosynthesis
Interleukin-6 - genetics
Intra-Abdominal Fat - drug effects
Intra-Abdominal Fat - immunology
Intra-Abdominal Fat - pathology
Macrophages - drug effects
Macrophages - immunology
Macrophages - secretion
Male
Middle Aged
Molecules
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - biosynthesis
RNA, Messenger - genetics
Subcutaneous Fat - drug effects
Subcutaneous Fat - immunology
Subcutaneous Fat - pathology
Thiazolidinediones - pharmacology
Tissues
U937 Cells
Vascular Cell Adhesion Molecule-1 - biosynthesis
Vascular Cell Adhesion Molecule-1 - genetics
Title Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages
URI http://ajpendo.physiology.org/cgi/content/abstract/296/5/E1076
https://www.ncbi.nlm.nih.gov/pubmed/19240250
https://www.proquest.com/docview/232315881
https://www.proquest.com/docview/67150080
Volume 296
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6FIiFeELQcoRz7gOABuW28Xq_9WKFUFbQlSIno22p3vYZAYle1g5T8Hf4os4ePqtwvVuL4WGc-z87MzsyH0AtFYqbAwQnyPGNBJEgKepAIMOSSTMkkZ6E2xcmnZ_HxLHp7Ts8Hg--9rKVVLffU5qd1Jf8jVdgHcjVVsv8g2faisAM-g3xhCxKG7V_JeDIvP5km25uyMOwn2cqnV4GUl271_NKlwLrOso6PT2Tzi1Kta9fboeHbqYz5WDtzFMbvDoCRLYXh-PoMWqfq27HtQk-v84QNkrjiF0P3U2QlaKSi6_G01DUgbtH0LLT62JQsCGfJVl9FF1ht49gf9Xwt_Oxq4_5yXleOvsp1QGgBOK8M_oJJWZXfqo0LCU_EUi_ElchG2uURNsHOlATggaZ9bR06AlwPS9rTvWPwZOPeRA7fHfvc9VmCmq6z4othGS73wGAaEZtV282JTR7A2Xt-NDs54dPx-fQGuhmCL2K0_7sPXUt6QyHsavLdYJvKLBruX7_DVeun6Uj9a-_GWjnTu-iOd0_wocPaPTTQxTbaOSwATcs1foknrYy30a1Tn5exgxZ9JGKPRNxHIm6RiMscWyTiDom4LrFHIm6QiOUat0jc7-HwPpodjadvjgPP4xGoiJA6oKlMlATDNWNwKSqYjnWeg2sM84uIyYgImHBpAra9TrVKiU6FPqA5TVgWyjBLyQO0VcDwHyFMlR7FpqiJ5SySUSJVBvpFZgnTjOmIDNGo-X-58k3uDdfKgltnl4bcy4RbmVgS1iF63Z5z4Vq8_PboV43YePdetQcCPDnlFopDtNtIlfuXseLwkASeNRkN0fP2V9DoZplOFLpcVTxm4KSBIzdEDx0UulGlZi2UHjz-47m76Hb3Rj1BW_XlSj8F67mWzyx6fwAIwtAF
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pioglitazone+reduces+inflammatory+responses+of+human+adipocytes+to+factors+secreted+by+monocytes%2Fmacrophages&rft.jtitle=American+journal+of+physiology%3A+endocrinology+and+metabolism&rft.au=Permana%2C+Paska+A&rft.au=Zhang%2C+Weiyang&rft.au=Wabitsch%2C+Martin&rft.au=Fischer-Posovszky%2C+Pamela&rft.date=2009-05-01&rft.issn=0193-1849&rft.volume=296&rft.issue=5&rft.spage=E1076&rft.epage=E1084&rft_id=info:doi/10.1152%2Fajpendo.91013.2008&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0193-1849&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0193-1849&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0193-1849&client=summon